Head injury is one of the older corners of the fisetin literature, predating the senolytic story by several years. It is also one of the areas where the research quality is genuinely better than average for this compound, and where the gap between what was studied and what a reader wants to do with it is widest.
Two audiences arrive at this topic. People recovering from a concussion, and former contact-sport athletes worried about chronic traumatic encephalopathy. The evidence is very different for those two questions, and the CTE evidence is much thinner than the search results suggest.
Key Takeaways
- In a 2018 mouse study, fisetin improved neurological function, reduced cerebral edema, shrank the brain lesion and protected the blood-brain barrier after experimental TBI.[1]
- That same study ran the control that matters: in Nrf2 knockout mice, fisetin failed to suppress oxidative stress at all, which ties the effect to a specific pathway rather than general antioxidant hand-waving.[1]
- A 2024 study extended this to repetitive mild closed head injury, the model closest to sports concussion, and traced the benefit to blocked ferroptosis via PI3K/AKT/NRF2.[2]
- Dose mattered and not gently: in a bleed model, 50 mg/kg improved outcomes while the 25 mg/kg arm did not.[3]
- The one long oral study pretreated rats for 12 weeks before inducing injury.[4]
- The CTE claim rests on a computer simulation of tau fibrils. No cells, no animals, no people.[5]
- No human trial has tested fisetin for concussion, TBI recovery, or CTE.
What the animal work actually found
The foundational paper is a 2018 mouse TBI study from Nanjing University.[1] Fisetin improved neurological scores, reduced brain swelling, limited the size of the lesion and preserved blood-brain barrier integrity. Markers moved the way you would want: malondialdehyde down, glutathione peroxidase activity restored, Bcl-2 up, Bax and caspase-3 down.
What separates this from the typical flavonoid paper is the knockout arm. The authors repeated the experiment in mice lacking Nrf2, the transcription factor that switches on antioxidant genes. In those animals fisetin did not suppress oxidative stress. That is a real mechanistic control, and it is the kind of evidence that distinguishes a specific pathway effect from a compound that simply mops up free radicals. Fisetin’s Nrf2 activation shows up across many tissues, and this is one of the cleaner demonstrations that it is doing the work.
A 2024 study built on this using repetitive mild closed head injury, which is the model that most resembles what happens to a football or hockey player.[2] Fisetin improved performance on the water maze and reduced brain water content, and the mechanism traced to ferroptosis, an iron-dependent form of cell death now understood to drive part of the secondary injury after a head impact. The authors confirmed the finding in cell models where ferroptosis was induced chemically.
A third study looked at early brain injury after subarachnoid hemorrhage, a bleed rather than an impact, and found reduced TLR4 and NF-kappa-B signalling.[3] It is worth reading that paper for the dosing detail alone, covered below.
The timing problem
Here is where the literature and the real world separate.
In the 2018 TBI study and the 2024 closed head injury study, fisetin was administered as part of a controlled protocol built around a scheduled injury. In the bleed study, treatment was given 30 minutes after the event.[3] In the traumatic epilepsy study, rats received oral fisetin at 20 mg/kg for twelve weeks before the injury was induced.[4]
Nobody schedules a concussion. You cannot pretreat a car accident, a fall, or a hit you did not see coming. The scenario these studies model is closest to a hospital administering a neuroprotective agent immediately after a known injury, which is a drug development pathway, not a supplement use case.
The twelve-week pretreatment study is the only one that resembles taking a daily capsule, and it was testing prevention of post-traumatic seizures in rats with iron injected into the cortex. That is a specific and unusual model.
The dose threshold nobody mentions
The subarachnoid hemorrhage study tested two doses, and only the higher one worked.[3] At 50 mg/kg fisetin significantly improved neurological function and reduced brain edema at both 24 and 72 hours. At 25 mg/kg it did not.
This matters more than it first appears. A threshold effect means the benefit is not a gentle dose-response curve where a smaller amount gives you a smaller benefit. Below the threshold, in that model, there was no measurable benefit at all. And 50 mg/kg in a rat, converted by body surface area, lands far above what a typical fisetin capsule delivers, before you even account for how little oral fisetin reaches the bloodstream.
About CTE specifically
Chronic traumatic encephalopathy is the reason many people search for this topic. It is a tauopathy, driven by tau protein aggregating into fibrils in the depths of the cortical folds, and it is associated with repeated head impacts.
There is exactly one fisetin paper addressing CTE directly, and it is a molecular dynamics simulation.[5] The researchers modelled two structural types of CTE-associated tau fibril on a computer and simulated what happens when fisetin molecules bind. The simulation suggests fisetin destabilises both fibril types by disrupting the hydrogen-bond network and reducing beta-sheet content.
That is interesting chemistry. It is not biology. No cells were involved, no animals were treated, and the authors themselves note that the short simulation time means they captured only early molecular events. They frame the work as information for designing drugs, which is the correct framing.
If you are a former athlete reading that fisetin clears the tau tangles behind CTE, the underlying source is a physics simulation. That deserves to be stated plainly, because the people most motivated by this claim are the ones with the most at stake.
Where fisetin sits among the alternatives
A 2025 review of nutraceuticals in TBI management placed fisetin alongside omega-3 fatty acids, curcumin, vitamin D, B vitamins, vitamin E, creatine, CoQ10, magnesium and zinc.[6] Fisetin’s listed contribution was reduced oxidative damage and inflammation through Nrf2 upregulation and NF-kappa-B suppression, described as showing potential in TBI models.
Notably, several compounds on that list have actual human trial data in head injury. Fisetin does not. A Salk Institute review of fisetin across neurological disorders reaches a similar place: a large and consistent preclinical record spanning Alzheimer’s, Parkinson’s, Huntington’s, ALS, stroke and TBI, with the conclusion that it would be worthwhile to pursue these effects in humans.[7] That was published in 2021 and the human TBI work still has not happened.
The pattern here is the same one visible in fisetin’s stroke research: broad protection across many acute brain injury models, which is encouraging and also exactly what a competent antioxidant produces on these endpoints.
What to take from this
If you have had a concussion, the priority is medical evaluation and a graded return to activity supervised by someone qualified. Nothing in the fisetin literature supports using it in place of that, and nothing in it was tested on a human brain.
If you are worried about CTE from a contact-sport history, the honest answer is that no supplement has been shown to prevent or treat it, and the fisetin claim specifically comes from a computer model.
The research is not bad. The Nrf2 knockout work is better controlled than most of what gets published about flavonoids. It is preclinical, it usually required dosing before or immediately after a scheduled injury, and in at least one model half the dose produced none of the benefit. Those are the details that decide whether a finding transfers to a bottle on a shelf. Fisetin’s general safety profile is reassuring enough that the risk of trying it is low, but low risk is not the same as evidence of benefit.
Frequently Asked Questions
Does fisetin help with concussion recovery?
No human study has tested it. In mice, fisetin improved neurological function, reduced brain swelling and protected the blood-brain barrier after experimental traumatic brain injury, including in a repetitive mild closed head injury model. In those studies fisetin was given as part of a protocol built around a scheduled injury, which is not how concussions happen in real life.
Is there evidence fisetin prevents CTE?
Only one study addresses chronic traumatic encephalopathy directly, and it is a molecular dynamics computer simulation of tau fibrils rather than an experiment in cells, animals or people. It suggests fisetin could destabilise CTE-associated tau fibrils. The authors present it as groundwork for drug design, and note the simulation captured only early molecular events.
What dose of fisetin was used in brain injury studies?
Doses varied widely. A subarachnoid hemorrhage study found 50 mg/kg improved outcomes while 25 mg/kg did not. A traumatic epilepsy study used oral fisetin at 20 mg/kg daily for twelve weeks before injury. Scaled to human equivalents by body surface area, these are well above what typical fisetin supplements provide.
References
- Fisetin alleviates oxidative stress after traumatic brain injury via the Nrf2-ARE pathway. Neurochem Int (2018). PMID 29792955
- Fisetin exerts neuroprotective effects in vivo and in vitro by inhibiting ferroptosis and oxidative stress after traumatic brain injury. Front Pharmacol (2024). PMID 39635435
- Fisetin alleviates early brain injury following experimental subarachnoid hemorrhage in rats possibly by suppressing TLR4/NF-kappaB signaling pathway. Brain Res (2015). PMID 26475978
- Antiepileptic effect of fisetin in iron-induced experimental model of traumatic epilepsy in rats. Nutr Neurosci (2017). PMID 27198489
- Molecular mechanisms involved in the destabilization of two types of R3-R4 tau fibrils associated with chronic traumatic encephalopathy by Fisetin. Phys Chem Chem Phys (2024). PMID 38197437
- Supplement and nutraceutical therapy in traumatic brain injury. Nutr Neurosci (2025). PMID 40440029
- Preventing and Treating Neurological Disorders with the Flavonol Fisetin. Brain Plast (2021). PMID 33782648
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.